Québec Heart and Lung Institute, Laval University, 2725 chemin Ste-Foy, Québec City, QC, Canada Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, USA.
Cardiology Department, AP-HP, Hôpital Bichat Claude Bernard, Paris, France University Paris Diderot, Sorbonne Paris Cité, Paris, France.
Eur Heart J. 2016 Jul 21;37(28):2217-25. doi: 10.1093/eurheartj/ehv756. Epub 2016 Jan 26.
Transcatheter aortic valve implantation (TAVI) has spawned the evolution of novel catheter-based therapies for a variety of cardiovascular conditions. Newer device iterations are delivering lower peri- and early post-procedural complication rates in patients with aortic stenosis, who were otherwise deemed too high risk for conventional surgical valve replacement. Yet beyond the post-procedural period, a considerable portion of current TAVI recipients fail to derive a benefit from TAVI, either dying or displaying a lack of clinical and functional improvement. Considerable interest now lies in better identifying factors likely to predict futility post-TAVI. Implicit in this are the critical roles of frailty, disability, and a multimorbidity patient assessment. In this review, we outline the roles that a variety of medical comorbidities play in determining futile post-TAVI outcomes, including the critical role of frailty underlying the identification of patients unlikely to benefit from TAVI. We discuss various TAVI risk scores, and further propose that by combining such scores along with frailty parameters and the presence of specific organ failure, a more accurate and holistic assessment of potential TAVI-related futility could be achieved.
经导管主动脉瓣植入术(TAVI)催生了多种心血管疾病的新型导管治疗方法。新型设备的迭代在主动脉瓣狭窄患者中实现了更低的围手术期和早期术后并发症发生率,这些患者如果接受传统的手术瓣膜置换术,风险太高。然而,在术后阶段,相当一部分当前的 TAVI 受者无法从 TAVI 中获益,要么死亡,要么表现出缺乏临床和功能改善。目前人们非常关注如何更好地识别 TAVI 后无效的预测因素。其中隐含的是脆弱性、残疾和多疾病患者评估的关键作用。在这篇综述中,我们概述了各种合并症在确定 TAVI 后无效结局中的作用,包括脆弱性在确定不太可能从 TAVI 中获益的患者中的关键作用。我们讨论了各种 TAVI 风险评分,并进一步提出,通过结合这些评分以及脆弱性参数和特定器官衰竭的存在,可以更准确和全面地评估潜在的 TAVI 相关无效性。
Heart Vessels. 2017-10
Eur Heart J. 2015-11-17
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2019-10-1
J Cardiovasc Dev Dis. 2024-9-4
Front Cardiovasc Med. 2024-1-15